Alopecia areata: current concepts

Alopecia areata (AA) is a chronic autoimmune condition causing non-scarring hair loss, affecting about 2% of the global population, with significant psychosocial impacts. Recent research has identified the collapse of immune privilege in hair follicles and activation of the JAK-STAT pathway as key factors in AA's onset. This has led to the development of targeted treatments, including the FDA-approved oral Janus kinase inhibitors baricitinib and ritlecitinib, marking a shift from traditional therapies. These treatments have shown efficacy in clinical trials, though they require continuous maintenance to prevent relapse and carry risks of serious infections. AA is often associated with other autoimmune diseases and psychiatric conditions, highlighting its complexity beyond a cosmetic disorder.